Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
OTHER OTC:BCLI
RESEARCH TOOLSreports
Total Valuation
Brainstorm Cell Therapeutics has a market cap or net worth of $7.91M. The enterprise value is $9.41M.
Market Cap$7.91M
Enterprise Value$9.41M
Share Statistics
Brainstorm Cell Therapeutics has 10,376,109 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10,376,109
Owned by Insiders8.06%
Owned by Institutions3.95%
Financial Efficiency
Brainstorm Cell Therapeutics’s return on equity (ROE) is -1.50 and return on invested capital (ROIC) is 177.25%.
Return on Equity (ROE)-1.50
Return on Assets (ROA)6.34
Return on Invested Capital (ROIC)177.25%
Return on Capital Employed (ROCE)1.64
Revenue Per Employee31.44K
Profits Per Employee-430.48K
Employee Count27
Asset Turnover0.46
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Brainstorm Cell Therapeutics is ―. Brainstorm Cell Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value-1.55
Price to FCF―
Price to Operating Cash Flow-0.60
PEG Ratio―
Income Statement
In the last 12 months, Brainstorm Cell Therapeutics had revenue of 849.00K and earned 11.62M in profits. Earnings per share was 2.19.
Revenue849.00K
Gross Profit849.00K
Operating Income-11.69M
Pretax Income11.62M
Net Income11.62M
EBITDA-11.31M
Earnings Per Share (EPS)2.19
Cash Flow
In the last 12 months, operating cash flow was -9.48M and capital expenditures -1.68M, giving a free cash flow of -9.48M billion.
Operating Cash Flow-9.48M
Free Cash Flow-9.48M
Free Cash Flow per Share-0.91
Dividends & Yields
Brainstorm Cell Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.56
52-Week Price Change-82.93%
50-Day Moving Average0.83
200-Day Moving Average1.34
Relative Strength Index (RSI)47.58
Average Volume (3m)54.95K
Important Dates
Brainstorm Cell Therapeutics upcoming earnings date is Nov 17, 2025, Before Open (Confirmed).
Last Earnings DateAug 14, 2025
Next Earnings DateNov 17, 2025
Ex-Dividend Date―
Financial Position
Brainstorm Cell Therapeutics as a current ratio of 0.04, with Debt / Equity ratio of -9.53%
Current Ratio0.04
Quick Ratio0.04
Debt to Market Cap0.00
Net Debt to EBITDA-0.05
Interest Coverage Ratio-151.86
Taxes
In the past 12 months, Brainstorm Cell Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Brainstorm Cell Therapeutics EV to EBITDA ratio is -1.11, with an EV/FCF ratio of -1.38.
EV to Sales14.82
EV to EBITDA-1.11
EV to Free Cash Flow-1.38
EV to Operating Cash Flow-1.38
Balance Sheet
Brainstorm Cell Therapeutics has $824.00K in cash and marketable securities with $577.00K in debt, giving a net cash position of -$247.00K billion.
Cash & Marketable Securities$824.00K
Total Debt$577.00K
Net Cash-$247.00K
Net Cash Per Share-$0.02
Tangible Book Value Per Share-$1.46
Margins
Gross margin is 61.48%, with operating margin of -1377.27%, and net profit margin of 1369.02%.
Gross Margin61.48%
Operating Margin-1377.27%
Pretax Margin1369.02%
Net Profit Margin1369.02%
EBITDA Margin-1331.68%
EBIT Margin-1359.95%
Analyst Forecast
The average price target for Brainstorm Cell Therapeutics is $6.60, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$6.60
Price Target Upside829.58% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast47.54%